Direct PeptidesProduct page includes use or preparation wordingIn stock
PT-141 (bremelanotide) · 10 mg × 10 vials
$799.00$7.99 / mg
Checked · 5 days ago
Lab report: Not linked
View product details (opens in a new tab)No commercial relationship
Research listings · Peptides
PT-141 (bremelanotide) research listings: prices and suppliers
Research materials and consumer products belong to different categories. A listing, laboratory report, or research-use label does not establish suitability for personal use.
We have no commercial relationship with suppliers on this page. Offers are sorted by price per mg; commission never changes the order.
Prices observed weekly · last check · How we check prices →
Lowest current at 10 mg × 10 vials$7.99 / mg · $799.00Direct Peptides · checked 5 days ago
Listings at 10 mg × 10 vials
| Supplier link | |||||||
|---|---|---|---|---|---|---|---|
| Direct PeptidesProduct page includes use or preparation wording | 10 mg × 10 vials | $799.00 | $7.99 / mg | In stock | 5 d ago | Not linked | View product details (opens in a new tab)No commercial relationship |
- Prices exclude shipping. A matching name does not verify the contents of a lot.
- Lab reports are vendor-reported, not independently authenticated. “Lab confirmed” means the issuing laboratory confirmed the report is theirs.
- Some suppliers’ product pages include use or preparation wording. We list their prices for comparison only; we do not endorse that wording, and nothing on this site is guidance on preparing or using these materials.
By size
Every package size we track for PT-141 (bremelanotide). Current means seen in the last 8 days.
| 10 mg × 1 vial | $24.99 | $2.50 / mg | 13 / 13 | 13 |
|---|---|---|---|---|
| 10 mg × 10 vials | $799.00 | $7.99 / mg | 1 / 1 | 1 |
| 10 mg × 1 bottle | $103.68 | — | 1 / 1 | 1 |
Research context
From our own records, with the date each was last checked.
- FDA approval
- Approved under NDA 210557 as Vyleesi (bremelanotide acetate injection), first approved 2019-06-21Checked
- 503A / 503B compounding
- Not in any 503A nomination category on FDA's 2026-05-14 list; bremelanotide acetate is the active ingredient of an FDA-approved drugChecked
- Advisory committee (PCAC)
- No PCAC discussion of bremelanotide found in FDA's 2022 to 2027 committee meeting materials (checked 2026-11-03)Checked
- Rulemaking / enforcement
- No proposed or final rule found (search on 2026-11-03); FDA's notices cover Vyleesi's patent-term review (2020) and a product-specific guidance (2021)Checked
- Identity
- Formula C50H68N14O10 · MW 1025.2 g/mol · CAS 189691-06-3Sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OHSource record Checked
Identity noteResearch listings are not Vyleesi and are not made or checked by its maker. PT-141 differs from melanotan II only at the C-terminal end: a free acid instead of an amide.
How we check prices · Offers are matched to our catalogue by an editor before they appear; a listing is not an endorsement.